Literature DB >> 7474944

Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.

A Gustavsson1, H Jahr, R Tobiassen, D R Jacobson, K Sletten, P Westermark.   

Abstract

BACKGROUND: In many different forms of amyloidosis, transthyretin (TTR) comprises the major amyloid fibril protein. In the familial forms, various TTR mutations are linked to disease. This study was designed to characterize the components of the TTR-derived amyloid fibril protein in senile systemic amyloidosis and to determine whether any mutation in the TTR gene was present. EXPERIMENTAL
DESIGN: Heart tissues from two patients with advanced senile systemic amyloidosis were studied. Amyloid fibrils were extracted and the amyloid fibril protein purified. The relationship between full-length and fragmented TTR and the amino acid sequence of the TTR were determined. The TTR gene was studied by single-strand conformation polymorphism analysis or direct sequencing.
RESULTS: In both cases, the amyloid deposits contained full-length TTR and a complex mixture of TTR fragments. The fragments, most of which had their N-termini at positions 46-52, predominated. No amino acid substitution was identified. The N-terminal fragment (1-45) was not identified in either patient. In each case, the four exons of the TTR gene were of normal sequence.
CONCLUSIONS: In familial amyloidosis resulting from deposition of TTR Met 30 (Swedish-type familial amyloidosis), full-length TTR molecules (some mutant) usually predominate, and TTR fragments lacking three of the eight beta-strands (nonmutant) form a major part of the fibril in senile systemic amyloidosis. This may indicate a difference in the fibrillogenesis between these two forms of TTR-derived amyloidosis. We propose that the name senile systemic amyloidosis be used only for normal-sequence TTR amyloidosis occurring in advanced age.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474944

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

Review 1.  Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.

Authors:  David C Seldin; John L Berk; Flora Sam; Vaishali Sanchorawala
Journal:  Heart Fail Clin       Date:  2011-05-20       Impact factor: 3.179

2.  Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.

Authors:  Taro Yamashita; Mitsuharu Ueda; Yohei Misumi; Teruaki Masuda; Toshiya Nomura; Masayoshi Tasaki; Kotaro Takamatsu; Keiko Sasada; Konen Obayashi; Hirotaka Matsui; Yukio Ando
Journal:  J Neurol       Date:  2017-11-24       Impact factor: 4.849

3.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

4.  Aggregates of denatured proteins stimulate nitric oxide and superoxide production in macrophages.

Authors:  Szczepan Jozefowski; Janusz Marcinkiewicz
Journal:  Inflamm Res       Date:  2009-09-26       Impact factor: 4.575

5.  Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores.

Authors:  Richard L Julius; Omar K Farha; Janet Chiang; L Jeanne Perry; M Frederick Hawthorne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-13       Impact factor: 11.205

6.  Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.

Authors:  Lawreen H Connors; Flora Sam; Martha Skinner; Francesco Salinaro; Fangui Sun; Frederick L Ruberg; John L Berk; David C Seldin
Journal:  Circulation       Date:  2015-12-11       Impact factor: 29.690

7.  Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.

Authors:  Celia M Torres-Arancivia; Deborah Chang; William E Hackett; Joseph Zaia; Lawreen H Connors
Journal:  Biochemistry       Date:  2020-11-03       Impact factor: 3.162

8.  Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.

Authors:  Anvesh K R Dasari; Jenette Arreola; Brian Michael; Robert G Griffin; Jeffery W Kelly; Kwang Hun Lim
Journal:  Biochemistry       Date:  2020-06-14       Impact factor: 3.162

9.  Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.

Authors:  P Patrizia Mangione; Riccardo Porcari; Julian D Gillmore; Piero Pucci; Maria Monti; Mattia Porcari; Sofia Giorgetti; Loredana Marchese; Sara Raimondi; Louise C Serpell; Wenjie Chen; Annalisa Relini; Julien Marcoux; Innes R Clatworthy; Graham W Taylor; Glenys A Tennent; Carol V Robinson; Philip N Hawkins; Monica Stoppini; Stephen P Wood; Mark B Pepys; Vittorio Bellotti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

10.  Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis.

Authors:  P Eldhagen; S Berg; L H Lund; P Sörensson; O B Suhr; P Westermark
Journal:  J Intern Med       Date:  2021-01-07       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.